Novo Nordisk (NVO)
(Delayed Data from NYSE)
$135.28 USD
+2.48 (1.87%)
Updated May 31, 2024 04:00 PM ET
After-Market: $135.58 +0.30 (0.22%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NVO 135.28 +2.48(1.87%)
Will NVO be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for NVO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NVO
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
NVO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now?
Beat the Market the Zacks Way: EverQuote, Micron, Amgen in Focus
Eli Lilly (LLY) to Ramp Up Indiana Site for Mounjaro, Zepbound
Other News for NVO
‘Stick with what's working' as markets head into June trade: Fundstrat’s Tom Lee
Unearthing Unknown Stocks: 3 Picks That Could Be the Next Big Thing
Novo Nordisk Is At The Vanguard Of The Weight Drug Revolution
Catalyst Watch: Nvidia stock split buzz, COMPUTEX, Walmart's annual meeting, and REITs on display
Novo Nordisk Sues Additional US Clinics Against Fake Semaglutide Products Used For Weight Loss, Diabetes